Patient-level pooled analysis of the effect of tiotropium on COPD exacerbations and related hospitalisations

Primary Care Respiratory Journal

Volumn 18, Issue 2, 2009, Pages 106-113

  Halpin, David ^a   Menjoge, Shailendra ^b   Viel, Klaus ^c  

^a ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

COPD; Exacerbations; Hospitalisations; Pooled analysis; Tiotropium

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; PLACEBO; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESEARCH; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; HAZARD RATIO; HOSPITALIZATION; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; OUTCOME ASSESSMENT; RISK ASSESSMENT; RISK REDUCTION; SENSITIVITY ANALYSIS; STEROID THERAPY; TREATMENT OUTCOME;

ADULT; AGED; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCOPOLAMINE DERIVATIVES; TREATMENT OUTCOME;

EID: 66549116089     PISSN: 14714418     EISSN: 14751534     Source Type: Journal    
DOI: 10.4104/pcrj.2009.00017     Document Type: Article

References (32)

1. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-852 http://dx.doi.org/10.1136/ thorax.57.10.847
2. Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-1422 (Pubitemid 28242071)
3. Bourbeau J, Ford G, Zackon H, Pinsky N, Lee J, Ruberto G. Impact on patients' health status following early identification of a COPD exacerbation. Eur Respir J 2007;30:907-913 http://dx.doi.org/10.1183/09031936.00166606
4. Connors AF, Jr., Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996;154:959-967
5. Soler-Cataluña JJ, Martínez-García MÁ, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60:925-931 http://dx.doi.org/10.1136/thx.2005.040527 (Pubitemid 41598207)
6. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. www.goldcopd.com. 2006. National Heart Lung and Blood Institute/World Health Organization.
7. Almagro P, Calbo E, Ochoa de Echaguen A, et al. Mortality after hospitalization for COPD. Chest 2002;121:1441-1448 http://dx.doi.org/10.1378/ chest.121.5.1441 (Pubitemid 34499653)
8. Ramsey SD, Sullivan SD. The burden of illness and economic evaluation for COPD. Eur Respir J Suppl 2003;41:29s-35s. http://dx.doi.org/10.1183/09031936. 03.00078203 (Pubitemid 36648152)
9. Hilleman DE, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest 2000;118:1278-1285 http://dx.doi.org/10.1378/chest.118.5.1278
10. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19:217-224 http://dx.doi.org/10.1183/09031936.02.00269802 (Pubitemid 34162820)
11. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003;58:399-404. (Pubitemid 36560942)
12. Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 2006;28:547-555 http://dx.doi.org/10.1183/09031936.06.00062705 (Pubitemid 43372529)
13. Tonnel A-B, Perez T, Grosbois J-M, Verkindre C, Bravo M-L, Brun M. Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD. Int J Chron Obstruct Pulmon Dis 2008;3:301-310
14. Chan CK, Maltais F, Sigouin C, Haddon JM, Ford GT. A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Can Respir J 2007;14:465-472
15. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005;143:317-326 (Pubitemid 41266605)
16. Barr RG, Bourbeau J, Camargo Jr CA, Ram FS. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006;61:854-862 http://dx.doi.org/10.1136/thx.2006.063271 (Pubitemid 44570305)
17. Powrie DJ, Wilkinson TM, Donaldson GC, et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in chronic obstructive pulmonary disease. Eur Respir J 2007;30:472-478
18. Casaburi R, Kukafka D, Cooper CB, Witek TJ, Jr., Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005;127:809-817 http://dx.doi.org/10.1378/chest.127.3.809 (Pubitemid 40775509)
19. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-56. http://dx.doi.org/10.1016/ S0140-6736(03)12459-12462 (Pubitemid 36173708)
20. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-919 http://dx.doi.org/10.1183/ 09031936.03.00027003 (Pubitemid 37540641)
21. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive disease. Eur Respir J 2003;21:74-81. http://dx.doi.org/10.1183/09031936.03.00031402 (Pubitemid 36150304)
22. Aaron SD, Fergusson D, Marks GB, et al. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax 2008;63:122-128 http://dx.doi.org/10.1136/thx.2007.082636
23. Griffin J, Lee S, Caiado M, Kesten S, Price D. Comparison of tiotropium bromide and combined ipratropium/salbutamol for the treatment of COPD: a UK General Practice Research Database 12-month follow-up study. Prim Care Resp J 2008;17:104-110 http://dx.doi.org/10.3132/pcrj.2008.00024
24. Senn S. The many modes of meta. Drug Inf J 2000;34:535-549 (Pubitemid 30351006)
25. ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group. Stat Med 1999;18:1905-1942
26. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004;59 Suppl 1:1-232.
27. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-1554 http://dx.doi.org/10.1056/NEJMoa0805800
28. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-1303. http://dx.doi.org/10.1136/bmj.320.7245. 1297 (Pubitemid 30245717)
29. Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-789 http://dx.doi.org/10.1056/NEJMoa063070 (Pubitemid 46294610)
30. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26. http://dx.doi.org/10.1164/rccm.200707-973OC
31. Lieberman D, Lieberman D, Gelfer Y, et al. Pneumonic vs nonpneumonic acute exacerbations of COPD. Chest 2002;122:1264-1270 http://dx.doi.org/10.1378/ chest.122.4.1264 (Pubitemid 35339539)
32. Kesten S, Plautz M, Piquette CA, Habib MP, Niewoehner DE. Premature discontinuation of patients: a potential bias in COPD clinical trials. Eur Respir J 2007;30:898-906. http://dx.doi.org/10.1183/09031936.00104606